Clinical trials located in

Tours

Tours city is located in France. Currently, 20 clinical trials are being conducted in this city.

Tours, nestled in the heart of the Loire Valley in France, is renowned for its rich history and vibrant cultural scene. This city, once a Gallic-Roman settlement, became a pivotal center during the Renaissance. Its architectural heritage is highlighted by the stunning Saint-Gatien Cathedral and the medieval Place Plumereau, lined with half-timbered houses. Tours is also celebrated for its gastronomy, particularly its wines and the traditional dish, rillettes. The city serves as a gateway to the Loire Valley’s famed châteaux, embodying a blend of historical grandeur and contemporary vitality.

  • CT-EU-00116279

    Study of KRT-232 Combined with Ruxolitinib for Myelofibrosis Patients

    This here clinical trial is looking at a new drug called KRT-232 that’s taken by mouth. The study aims to see if combining KRT-232 with the existing drug ruxolitinib can help folks with myelofibrosis who ain’t responding well enough to just taking ruxolitinib alone.

    The main goal in the first part of the study is to find the right dose of KRT-232 to use when combined with ruxolitinib. They’ll be looking closely at any side effects to make sure the dose is safe. In the second part, they’ll check if the combination of the two drugs can shrink the size of the spleen by at least 35% after 6 months of treatment.

    • KRT-232
    • Ruxolitinib
  • Combining Azacitidine and Venetoclax for Higher-Risk Chronic Myelomonocytic Leukemia

    The AVENHIR study is an open-label clinical trial for patients with higher-risk chronic myelomonocytic leukemia, a type of blood cancer. This study will evaluate the effectiveness and safety of combining two drugs: Azacitidine and Venetoclax (also known as ABT-199). Azacitidine is a chemotherapy drug, while Venetoclax is a targeted therapy that works by blocking a specific protein in cancer cells.

    The main goals of the study are to determine the overall response rate to this drug combination, which means how many patients achieve complete remission, partial remission, or clinical benefit. The study will also closely monitor safety and any potential dose-limiting side effects during the first two treatment cycles.

    To be eligible for this study, patients must be newly diagnosed with higher-risk chronic myelomonocytic leukemia and have not received any prior treatment with hypomethylating agents like Azacitidine.

    • Venetoclax
  • Exploring a new treatment combination for rheumatoid arthritis: baricitinib plus anti-TNF

    This clinical trial is focused on finding a more effective treatment for people with Rheumatoid Arthritis (RA) who haven’t responded well to previous therapies. The study is comparing two different approaches: one group will receive a combination of baricitinib treatment and an anti-TNF therapy (adalimumab), while the other group will receive baricitinib along with a placebo. The main goal is to see which group shows a greater improvement in their RA symptoms, specifically looking for a 50% improvement in symptoms, known as an ACR 50 response, after 24 weeks from the start of the treatment.

    Baricitinib is a medication that targets certain pathways in the body’s immune system to reduce inflammation and pain in RA. Anti-TNF therapy, like adalimumab, works by blocking the action of a protein in the body that causes inflammation. By combining these two treatments, researchers hope to see a more significant improvement in RA symptoms than with baricitinib alone.

    The trial is important because it aims to provide a new option for patients with RA who have not found relief with current treatments. It’s designed to test the safety and effectiveness of using these two different types of medications together.

    • placebo
    • Adalimumab
    • Baricitinib
  • Comparison of zibotentan/dapagliflozin with dapagliflozin alone in the treatment of chronic kidney disease with high proteinuria

    The study aims to understand how to better treat people with chronic kidney disease (CKD) and high proteinuria. This study is in its third phase and involves multiple centers where participants will be closely monitored. The main goal is to compare the effectiveness, safety, and how well participants tolerate a combination treatment of zibotentan/dapagliflozin versus dapagliflozin alone.

    During this study, participants will be randomly assigned to one of two groups. One group will receive the combination of zibotentan and dapagliflozin, while the other group will receive only dapagliflozin. Both treatments aim to slow down the decline in kidney function, which is a major concern for people with CKD and high proteinuria. The key measure of success for this study is the change in eGFR from baseline, which is a test used to check how well the kidneys are working, specifically by measuring the estimated glomerular filtration rate (eGFR). This will be assessed at the 24-month mark of the study.

    This research is crucial because it could lead to better treatment options for those suffering from CKD and high proteinuria, potentially improving their quality of life and health outcomes.

    • Zibotentan/Dapagliflozin
    • Dapagliflozin
  • CT-EU-00083874

    Study to find the best way to administer pegaspargase in children with acute lymphoblastic leukemia

    This is a study to investigate treatment strategies for children and adolescents diagnosed with acute lymphoblastic leukemia (ALL). The study focuses on evaluating the efficacy of a drug called pegaspargase. The drug works by depriving tumor cells of essential nutrients, contributing to its potential efficacy against ALL in pediatric patients. The study aims to determine the optimal way to administer pegaspargase, comparing a single high dose with two lower doses, with additional doses later in treatment. For those at highest risk, a more intensive treatment plan is being investigated. This includes two larger initial doses, followed by additional doses later in treatment. The study is evaluating factors such as potential serious side effects and overall treatment efficacy.

    • pegaspargase
  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    • Enzalutamide/Xtandi
    • Darolutamide/Nubequa
    • Abiraterone Acetate/Zytiga
    • Saruparib
  • Continued Parsaclisib treatment for B-cell cancer patients

    This is a phase II clinical trial focused on providing continuation of treatment with a drug called parsaclisib to people diagnosed with B-cell malignancies. The main goal of this study is to expand the treatment regimen established in the previous study. Study participants will receive parsaclisib as a stand-alone therapy (monotherapy) or in combination with other therapeutic agents, which may include itacitinib, ruxolitinib or ibrutinib. The study aims to facilitate participants’ ongoing care and contribute to the broader field of medical research by collecting data on the effectiveness and safety of prolonged use of parsaclisib.

    • Ibrutinib
    • Ruxolitinib
    • Itacitinib
    • Parsaclisib
  • Studying new potential drug with atezolizumab for non-small cell lung cancer

    This study is looking at a new cancer drug called GB1211, used along with another drug called Atezolizumab, to treat a type of lung cancer called Non-Small Cell Lung Cancer (NSCLC). The study aims to see how safe GB1211 is and how well it works. It is separated into three parts, where the first part helps in figuring out the right dose. In this part, two groups of 4 patients each will receive either 200 mg or 400 mg doses of GB1211 along with Atezolizumab, after which their health changes will be monitored. Patients can continue treatment for 12 weeks if it helps. In the next part, more patients will join, some getting GB1211 and some a placebo, to see how well it works. Depending on how they respond over 12 weeks, they might get offered the chance to carry on with the treatment in the third part of the study. After the study is over, researchers will check all patients for any side effects happened after 4 weeks.

    • Selvigaltin
    • Atezolizumab
  • Study on luspatercept treatment for Myelodysplastic Syndrome

    This study is looking into a medication named Luspatercept and how safe and effective it is for people who have a blood condition known as lower-risk Myelodysplastic Syndrome, or LR-MDS for short. These individuals often need transfusions or have their blood refreshed with new, healthy red blood cells. The drug will be given at its highest approved dose to see what effect it has. This is being done in a controlled and careful way to make sure everything is safe for the participants in the study. People who are taking part in this study have been identified as having a very low to medium risk according to the International Prognostic Scoring System (IPSS-R). This means their disease isnt considered high-risk, which makes them suitable candidates for this research. The study is open-label, meaning everybody knows what is in the drug they are getting.

    • Luspatercept
  • Study on sonrotoclax’s effects on returning mantle cell lymphoma

    In this medical trial, doctors are studying the effects of a medication, sonrotoclax (BGB-11417), on people suffering from a type of hard-to-treat blood cancer known as mantle cell lymphoma, which has come back or has not responded to previous treatments. The study is divided into two sections. In the first part, doctors will focus on finding how safe and tolerable this new drug is, the highest dose one can safely take, and the best dose for phase 2 studies. In the second part, they will study how effectively this medicine can treat the cancer at the best dose found in part one. The trial offers hope for better outcomes by exploring this new therapy option, aiming to improve the quality of life for patients facing this challenging condition.

    • BGB-11417/Sonrotoclax
  • Study on the efficacy of pirtobrutinib for mantle cell lymphoma

    This clinical trial is designed for patients diagnosed with mantle cell lymphoma (MCL), a type of blood cancer. The primary objective of the study is to assess the efficacy of a new drug called pirtobrutinib in comparison to other similar drugs that have received approval from the U.S. Food and Drug Administration (FDA). Participants may be involved in the study for a duration of two years or more, contingent on their condition not worsening. The trial will categorize patients into two groups: one receiving pirtobrutinib, and the other receiving either ibrutinib, acalabrutinib, or zanubrutinib, which are existing FDA-approved drugs for this condition. Throughout the study, the participants’ health condition, symptoms, and any side effects will be closely monitored. Additionally, the effectiveness of the treatments will be measured by evaluating the eventual survival rates of the patients.

    • Pirtobrutinib/LOXO-305
    • Zanubrutinib
    • Ibrutinib
    • Acalabrutinib
  • Testing new medicine for resistant high blood pressure

    In this 20-week trial, the effectiveness, safety, and optimal dosage of a medication known as XXB750 are being evaluated in individuals with resistant high blood pressure (resistant hypertension). This condition persists despite the use of three different blood pressure medications. XXB750 will be administered through subcutaneous injections, and its efficacy will be compared to a placebo. A 2-week preparation period precedes the trial, during which participants receive three doses of the actual trial medicine and one dose as part of the preparation. Following the trial, participants will be monitored for an additional 8 weeks without receiving any trial medicine during this period. The primary focus is on assessing whether XXB750 can effectively reduce blood pressure when measured over a 24-hour period.

    • XXB750
  • Investigating new treatment method for specific head and neck squamous cell carcinoma

    This clinical trial is focused on evaluating the safety and efficacy of a new treatment for patients with a specific type of head and neck cancer caused by Human Papilloma Virus 16 (HPV16) and characterized by the presence of the PD-L1 protein. The treatment involves a combination of a novel drug, BNT113, and a known drug, pembrolizumab. The primary objective is to determine whether this combination is more effective than pembrolizumab alone in assisting the body’s immune system in fighting the cancer. The trial is divided into two parts. In the initial phase, the focus is on assessing the safety of the new drug combination. Subsequently, in the second phase, patients will be randomly assigned to receive either the new combination or pembrolizumab alone. The trial aims to compare the outcomes of the two groups, evaluating tumor response (whether tumors shrink, remain the same, or grow) and monitoring any potential side effects resulting from the treatment.

    • BNT113
    • Pembrolizumab
  • Sotatercept treatment study for new Pulmonary Hypertension patients

    This study is an important test where doctors are looking at how a drug called Sotatercept can help people struggling with Pulmonary Arterial Hypertension (or PAH for short). The goal is to see whether this drug can delay or prevent the condition from getting worse. PAH makes it really hard for patients to breathe because it affects lungs and heart. The testing process is being done in a fair and careful way. Half of the patients will get the drug, and the others will get a ‘placebo’ which doesnt contain any medicine. The doctors will look at the effect on patients over time. The study is looking specifically at patients who were recently diagnosed with PAH and are at risk for the disease to get worse.

    • Sotatercept
  • Research on plitidepsin effectiveness in treating COVID-19

    This research study aims to investigate the benefits and safety of a drug called plitidepsin for COVID-19 patients who have a weakened immune system and require hospital care. The study will administer the drug to some patients, while others will receive standard care, allowing researchers to assess whether plitidepsin can reduce death rates in this specific population. Throughout the study, close monitoring will be conducted to observe any changes, including side effects, serious incidents, or the necessity to discontinue the treatment.

    • Plitidepsin
  • Testing the safety and effectiveness of alpelisib for MCAP syndrome

    This study is testing a medication called Alpelisib in people with a rare condition called Megalencephaly-Capillary Malformation Polymicrogyria Syndrome (MCAP). The study will be split into two sections. The first is a 6-month trial where some people will be given Alpelisib and others a placebo (a harmless, inactive substance), but no one will know which group they are in. This is to precisely measure the medication’s effects. After this, all qualifying participants will receive Alpelisib for the remaining 18 months. Participants’ progress will be monitored regularly, and the effects of the medicine will be assessed primarily using a scale that measures improvement in everyday skills and quality of life. The study also examines the medicine’s impact on brain growth and function using MRI scans and other tests.

    • Alpelisib
  • Studying ustekinumab treatment for Crohn’s perianal fistula

    This is a medical study being conducted to examine how effective a certain medication, called Ustekinumab, can be for people suffering from Crohn’s disease, specifically a subset called perianal Crohn’s. A group of people suffering from moderate to severe forms of this disease will be randomly assigned to receive either the actual medication or a placebo. Their symptoms will then be tracked for a period of 48 weeks to see if the medication helps lessen their symptoms. The end goal is to see whether the drug is useful in stopping all abnormal openings (fistulas) from draining. The study also aims to ensure that the drug doesn’t cause any buildup of more than 2 cm.

    • Ustekinumab
  • Different treatment combinations for advanced pancreatic cancer study

    This trial is about trying out different ways to control late-stage pancreatic cancer. The current standard treatment for patients with this type of cancer is a mix of drugs called FOLFIRINOX (Leucovorin (Folinic Acid), Fluorouracil, Irinotecan). However, doctors are not sure when they should stop or reduce this treatment after the cancer has been controlled for a while. So, in this study, they want to see if a new drug called OSE2101 can help keep the cancer from getting worse. Patients will either get OSE2101 with FOLFIRI (a kind of maintenance therapy), or FOLFIRI alone after the FOLFIRINOX treatment is stopped. The study also aims to assess the safety of OSE2101 in patients with advanced pancreatic cancer.

    • Tedopi/OSE2101
    • Irinotecan
    • Leucovorin
    • Fluorouracil
  • Testing ADT with or without darolutamide in prostate cancer patients

    This study is about testing how well two different kinds of prostate cancer treatment work. One treatment is called ADT (Androgen deprivation therapy) and the other is called darolutamide. In total, around 300 men who have just been diagnosed with prostate cancer will take part. The people in the study will be split into two groups. Half of the people will have the ADT treatment with placebo, while the other half will have both the ADT and darolutamide treatment. This will help the researchers understand whether adding darolutamide makes the ADT treatment work better. To check how well the treatment is working, the researchers will be using different methods.

    • Androgen deprivation therapy
    • Darolutamide
  • Study on treating uncontrolled bleeding with bentracimab

    A trial investigating bentracimab’s ability to reverse ticagrelor’s effects in patients with severe bleeding or those needing urgent surgery. The study, involving at least 200 patients from various regions, tests if bentracimab can quickly counteract ticagrelor, improving patients’ conditions or allowing for safe surgeries. Patients receive a thorough follow-up to ensure the drug’s effectiveness and safety, aiming to provide a reliable treatment for critical, time-sensitive medical scenarios.

    • bentracimab/PB2452

See more clinical trials in other cities in France:

.